Sarcosine


Glycine reuptake inhibitor (GlyT1)

N-methylglycine; an endogenous methylglycine that inhibits glycine reuptake at GlyT1, elevating synaptic glycine.

Abstract

Sarcosine (N-methylglycine; CAS 107-97-1; molecular formula C3H7NO2; molecular weight 89.09) is an endogenous N-methylated derivative of glycine and a competitive substrate of the glycine transporter type 1 (GlyT1). Pharmacologically, sarcosine inhibits glycine reuptake at GlyT1, elevating extracellular glycine concentrations near NMDA receptors and consequently enhancing NMDA receptor function via the glycine co-agonist site. The mechanism complements direct D-serine administration. Phase 2 trials in schizophrenia (as adjunct to risperidone or olanzapine) and major depressive disorder have shown small to moderate effects on negative symptoms and depressive symptoms. Plasma half-life is approximately 7 hours; the compound is well tolerated. The selective GlyT1 inhibitor bitopertin (RG1678) was developed as a more potent alternative but failed phase 3 trials. Used as the canonical GlyT1 substrate inhibitor in NMDA receptor research.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph